General Information of This Linker
Linker ID
LIN0JDAZC
Linker Name
Val-Asn linker
Linker Type
Cathepsin-cleavable linker
Antibody-Linker Relation
Cleavable
Structure
Formula
C11H18BrN3O5
Isosmiles
OC([C@H](CC(N)=O)NC([C@H](C(C)C)NC(CBr)=O)=O)=O
InChI
InChI=1S/C11H18BrN3O5/c1-5(2)9(15-8(17)4-12)10(18)14-6(11(19)20)3-7(13)16/h5-6,9H,3-4H2,1-2H3,(H2,13,16)(H,14,18)(H,15,17)(H,19,20)/t6-,9-/m0/s1
InChIKey
BWLCBSRSDQIRLT-RCOVLWMOSA-N
Pharmaceutical Properties
Molecule Weight
352.185
Polar area
138.59
Complexity
367.4995491
xlogp Value
-1.0331
Heavy Count
20
Rot Bonds
8
Hbond acc
4
Hbond Donor
4
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
38283215 ADC 23 [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.53 ug/mL
High TNF expression (TNF +++)
Method Description
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.

   Click to Show/Hide
In Vitro Model Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia K562 cells (TNF) CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 36 ug/mL Negative TNF expression (TNF-)
Method Description
ADC1-ADC27 with a DAR value of ~4 were screened in a GRE luciferase reporter assay in K562 cells over expressing mTNF and wild-type K562 cells to assess potency resulting from targeted delivery vs. nonspecific uptake. All the ADCs were inactive in the wild-type cells, suggesting the activity seen in mTNF over expressed cells was through targeted ADC uptake followed by intracellular release of compound C1.

   Click to Show/Hide
In Vitro Model Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia K562 cells (wt) CVCL_0004
References
Ref 1 Impact of dipeptide on ADC physicochemical properties and efficacy identifies Ala-Ala as the optimal dipeptide